The safety and efficacy of CTX110, an allo anti-CD19 CAR-T cell product modified by using CRISPR/Cas9 editing to disrupt the endogenous TRAC locus and disrupt β2M, which eliminates major histocompatibility complex (MHC) class I expression, are under evaluation in R/R LBCL, double/triple hit lymphoma, transformed FL, and FL grade 3b. The gene discussed is CD19; the disease is lymphoma.